GlassScriptPhysician profile
Vanh Luangphakdy
NPI 1487834172
$3,819.30
in general payments reported to CMS, 2019-2025
29 companies · $348 in 2025
The $348 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $236 · 2020: $309 · 2021: $506 · 2022: $567 · 2023: $1,117 · 2024: $735 · 2025: $348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,200.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $563.97 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Glaxosmithkline, LLC. | $499.95 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $469.10 | 2022-2024 | |
| Exact Sciences Corporation | $409.98 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $393.38 | 2019-2024 | Repatha, Otezla, Prolia |
| Novo Nordisk INC | $339.79 | 2019-2023 | Ozempic, Rybelsus |
| Pfizer INC. | $135.71 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.51 | 2019-2024 | |
| Abbvie INC. | $115.48 | 2021-2024 | |
| Daiichi Sankyo INC. | $92.65 | 2020-2025 | Injectafer |
| Amarin Pharma, INC. | $70.11 | 2019-2021 | |
| Boston Scientific Corporation | $57.79 | 2019-2025 | Wavewriter Alpha Prime 16 |
| Merck Sharp & Dohme LLC | $54.96 | 2020-2023 | Gardasil 9, Pneumovax 23, Vaxneuvance |
| Novartis Pharmaceuticals Corporation | $46.55 | 2022-2023 | |
| Abbott Laboratories | $43.82 | 2020-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $43.40 | 2019-2025 | Airsupra |
| Biohaven Pharmaceuticals, INC. | $40.68 | 2021 | |
| Astellas Pharma US INC | $39.21 | 2019-2023 | Myrbetriq |
| Philips North America LLC | $36.51 | 2024 | (Ck7) Extended Holter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.90 | 2022-2023 | Xifaxan |
| Bausch Health US, LLC | $35.64 | 2022-2023 | Aplenzin, Wellbutrin |
| Abiomed | $24.88 | 2023 | Impella |
| Biohaven Pharmaceutical Holding Company LTD. | $22.10 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $21.89 | 2019 | |
| Vertos Medical, INC. | $20.61 | 2024 | Mild Device Kit |
| Sanofi Pasteur INC. | $19.75 | 2019 | |
| Idorsia Pharmaceuticals US INC | $19.65 | 2023 | Quviviq |
| Phathom Pharmaceuticals, INC. | $17.46 | 2024 | Voquezna |
| Radius Health, INC. | $12.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vanh Luangphakdy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.